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Is off-label use of drugs legal?
A
nyone who has attended ophthal-
mology conferences recently can-
not fail to notice the enthusiasm
of retinal specialists in adopting the new
treatment, Avastin. Avastin is a huma-
nised monoclonal antibody against vas-
cular endothelial growth factor: an
important growth factor for angiogen-
esis. The labelled indication of Avastin is
for the treatment of colon cancer. Its use
in the eye is therefore off label; no
robust scientific data exist on its safety
and efficacy; all the positive reports have
short follow-ups. The clamour to intro-
duce this treatment raises several ethical
issues.
IS IT LEGAL?
Off-label use of drugs is not illegal.
Physicians and surgeons are allowed to
do this. It is not uncommon. In a
paediatric hospital ward setting, almost
half the prescriptions are unlicensed or
are off label.1 Intravitreal Triamcinolone,
tissue plasminogen activators, intracam-
eral Vancomycin or Lignocaine are just a
few off-label drugs used in ophthalmol-
ogy. The fact that it is common practice
does not make it safe. There may be a
risk of unexpected adverse outcomes,
but this is also true of labelled use of
new drugs. Some adverse effects do not
become apparent until after several
years of use or many thousands of
prescriptions; Vioxx2 is a good example.
APPROVED AND PROVEN
Approved and proven are not synon-
ymous terms, especially with new treat-
ment. A treatment can be proven
effective and safe but not be approved
because it is too costly. Good evidence
from randomised control trials (RCT)
shows that photodynamic therapy
(PDT) compared to no treatment is
effective in predominantly classic
lesions.3 The National Institute for
Health and Clinical Excellence (NICE)
does not recommend PDT for predomi-
nantly classic lesions, except in the
context of a study.4 Good evidence
shows that PDT is also effective in
treating small occult lesions and dete-
riorating vision.5 NICE has not approved
this because it has not considered it. In
most European countries PDT for occult
lesions is approved. Equally, Macugen is
a licensed and proven effective treat-
ment, but its approval is pending an
appraisal process that is not due to
report for more than 12 months. In the
USA, the Food and Drug Administration
(FDA)-approved treatments are PDT
and Macugen. A recent survey indicated
that most ophthalmologists believe
Avastin to be equally or more effective
than the FDA-approved treatment. The
American Academy of Ophthalmology
has asked the insurance companies to
approve and pay for Avastin, even





For dramatically effective treatment,
randomised trials are not necessary.
Many well-known examples of such
treatments exist: penicillin for bacterial
infections; smallpox vaccination; thyr-
oxine for hypothyroidism; vitamin B12
replacement; insulin for insulin-depen-
dent diabetes; anaesthesia for surgical
operations; and the immobilisation of
fractured bones. In all these examples,
observational studies were adequate to
show effectiveness.6 Equipoise is the
only justification for randomisation. If
a treatment is clearly superior, rando-
misation will put one group of patients
at a disadvantage. Randomisation is
necessary to avoid bias in case selection
and interpretation of the results. In wet
age-related macular degeneration
(AMD), good objective measures of
outcome are seen. In the UK, the only
NICE-approved treatment for AMD is
PDT, and this is limited to classic lesions
with no occult lesions. Is it irresponsible
to use an unproven treatment instead of
an approved treatment? If it is not, is it
ethical to perform a randomised trial of
PDT versus Avastin? Some think the
only ethical trial is between Lucentis
and Avastin.
IS IT FAIR AND TO WHOM?
We are grateful to drug companies that
have invested large amounts of research
money and effort on developing new
treatment. In the case of Avastin, its use
initially was based on the first-year
results of Lucentis.7 Avastin is in fact
the mother molecule and Lucentis a
fragment of this, with the active bind-
ing sites. Lucentis was developed
because it was thought that Avastin
would not penetrate the full thickness
of the retina and might not be effective
in choroidal neovascularisation.8 Case
series of Avastin showed results that
were comparable to Lucentis. It is
difficult to estimate, but Avastin has
probably been used on .10 000 patients
worldwide, with few documented com-
plications.9–16
In divided doses, Avastin may cost
only a few pounds per injection.
Lucentis, when licensed, is not likely to
be cheap. If Herceptin or Macugen
provides a guide, then the cost might
be several thousands of pounds per
patient per year. Both Lucentis and
Avastin are produced by the same
company, Genentech, San Francisco,
USA. Assuming that Lucentis gets a
licence in 6 months, doctors will have
the dilemma of a choice between the
two: with an expensive and proven
treatment on the one hand and a cheap
treatment with many unanswered ques-
tions on the other. Is it fair that
Genentech should lose out? What of
the patients (or countries) who cannot
afford Lucentis? Is it fair that treatment
is available to only those who are
wealthy?
RIGHTS AND DUTY
No one has any right (to a treatment)
unless someone else has a duty to
provide it. In modern societies the duty
to provide healthcare is established by
law on the government. The NHS is free
at the point of delivery. This does not
mean that all treatments can be
afforded and funded out of taxation.
The courts stated that ‘‘the (European)
Convention (on human rights) does not
give applicants the right to free health-
care in general,’’ and emphasised the
right of the government to determine
healthcare priorities.17 No patient has
any legal right to an expensive treat-
ment until NICE recommends it and
charges the primary care trusts (PCT) to
fund the treatment. NICE undoubtedly
needs time to appraise and consult. In
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‘‘IS MY EYE TREATABLE,
DOCTOR?’’
To the next patient with a minimally
classic lesion, what should we say?
Do we say, ‘‘No! there is no approved
treatment’’?
Do we say, ‘‘Yes, there is a proven
treatment, but you are not entitled to it as
the government has not agreed to fund
this expensive treatment. We can try and
apply to your local health authority for
funding. It is unlikely that every patient
applied for will be funded.’’
Or, do we say, ‘‘There is an unap-
proved treatment, which seems to be
effective, safe and affordable, but the
evidence is not of the highest order. Like
any new treatments, there is no long-
term safety and efficacy data.’’
DUTY OF CARE: WHO CARES?
The introduction of Avastin has created
a dilemma. Doctors are torn. We are
constantly urged to practice evidence-
based medicine. Equally importantly,
doctors need to practise medicine com-
passionately and ethically. Difficult
decisions are often reduced to simple
bottomline type analyses: what would
you do if the patient sitting in front of
you is your mother and she is losing
vision fast? The present difficulties over
Avastin echo the fuss made when
another apparent wonder drug,
Steptomycin, was introduced for treat-
ment of tuberculosis. There was resis-
tance to randomisation (a novel concept
then) as benefits of treatment were
obvious and compelling, but randomisa-
tion won the day. The only way a patient
could receive the drug was to agree to
enter the trial (this in itself was ethically
questionable). An exception was the
case of a physician who contracted
tuberculosis while the trial was still
running. He was not entered into the trial
but received the new drug anyway.18
Some doctors opt to advise the patient
to pay for the drug and to have private
treatments. A few doctors genuinely try
to seek research funding and mount
studies to treat patients. Yet others write
a case of needs, apply to hospital
medicine committees, write to PCTs
and plead for funding on a case-by-case
basis. The work required to introduce a
new treatment is substantial; the stan-
dard ethics application form is 60 pages
long; a pathway of care includes several
nights on the computer; a case of needs
requires many meetings with managers
and colleagues.
It is becoming increasingly difficult
for a doctor to discharge his or her duty
of care. But unless the doctor is willing
to do so, who else will be the patient’s
advocate?
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